• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鼻型结外NK/T细胞淋巴瘤的临床异质性:韩国癌症研究组的全国性调查

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group.

作者信息

Kim T M, Lee S-Y, Jeon Y K, Ryoo B-Y, Cho G J, Hong Y S, Kim H J, Kim S-Y, Kim C S, Kim S, Kim J S, Sohn S K, Song H H, Lee J L, Kang Y K, Yim C Y, Lee W S, Yuh Y J, Kim C W, Heo D S

机构信息

Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine.

Department of Pathology, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine.

出版信息

Ann Oncol. 2008 Aug;19(8):1477-1484. doi: 10.1093/annonc/mdn147. Epub 2008 Apr 2.

DOI:10.1093/annonc/mdn147
PMID:18385201
Abstract

BACKGROUND

This national survey was undertaken to propose the classification of extranodal natural killer (NK)/T-cell lymphoma (NTCL) subtypes and to clarify a clinical heterogeneity.

PATIENTS AND METHODS

Two hundred and eighty patients newly diagnosed as NTCL were enrolled from 22 Korean medical centers. Two subsets were compared: one involving the upper aerodigestive tract (UAT) and another involving the non-upper aerodigestive tract (NUAT) region, which comprises the skin, gastrointestinal tract, and liver or soft tissues. Clinical prognostic factors, survival outcomes, and independent predictors for survival were compared between each subset.

RESULTS

NUAT-NTCL (59 patients) had significantly higher proportions of disseminated disease, aggressive biologic features, and unfavorable host reactions compared with UAT-NTCL (221 patients). NUAT-NTCL had shortened 5-year overall survival (OS) (22% versus 41%, P = 0.001). Ann Arbor staging, the International Prognostic Index, and the NTCL prognostic index failed to predict the OS of NUAT-NTCL, but did predict the OS in UAT-NTCL. Independent predictors for OS by multivariate analyses differed between each subset. In the NUAT subset, extranodal sites and regional nodes predicted the OS, while Ann Arbor staging, age, performance status, and lactate dehydrogenase level predicted the OS in the UAT subset.

CONCLUSION

NUAT-NTCL may represent a distinctive disease entity in terms of clinical factors, independent predictors, and survival outcomes.

摘要

背景

开展这项全国性调查旨在提出结外自然杀伤(NK)/T细胞淋巴瘤(NTCL)亚型的分类方法,并阐明其临床异质性。

患者与方法

从22家韩国医疗中心招募了280例新诊断为NTCL的患者。比较了两个亚组:一个涉及上呼吸消化道(UAT),另一个涉及非上呼吸消化道(NUAT)区域,后者包括皮肤、胃肠道、肝脏或软组织。比较了每个亚组的临床预后因素、生存结果及生存的独立预测因素。

结果

与UAT-NTCL(221例患者)相比,NUAT-NTCL(59例患者)的播散性疾病比例、侵袭性生物学特征及不良宿主反应比例显著更高。NUAT-NTCL的5年总生存率(OS)缩短(22%对41%,P = 0.001)。Ann Arbor分期、国际预后指数及NTCL预后指数未能预测NUAT-NTCL的OS,但能预测UAT-NTCL的OS。多因素分析得出的OS独立预测因素在每个亚组中有所不同。在NUAT亚组中,结外部位和区域淋巴结可预测OS,而在UAT亚组中,Ann Arbor分期、年龄、体能状态及乳酸脱氢酶水平可预测OS。

结论

就临床因素、独立预测因素及生存结果而言,NUAT-NTCL可能代表一种独特的疾病实体。

相似文献

1
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group.鼻型结外NK/T细胞淋巴瘤的临床异质性:韩国癌症研究组的全国性调查
Ann Oncol. 2008 Aug;19(8):1477-1484. doi: 10.1093/annonc/mdn147. Epub 2008 Apr 2.
2
Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies.结外 NK/T 细胞淋巴瘤,鼻型:新的分期系统与治疗策略。
Cancer Sci. 2009 Dec;100(12):2242-8. doi: 10.1111/j.1349-7006.2009.01319.x. Epub 2009 Aug 19.
3
Characteristics, Prognostic Factors, and Survival of Patients with NK/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center Experience.非上呼吸消化道 NK/T 细胞淋巴瘤患者的特征、预后因素和生存:17 年单中心经验。
Cancer Res Treat. 2019 Oct;51(4):1557-1567. doi: 10.4143/crt.2018.681. Epub 2019 Apr 1.
4
Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.原发部位和区域淋巴结受累是早期结外鼻型自然杀伤/T细胞淋巴瘤的独立预后因素。
Chin J Cancer. 2016 Apr 4;35:34. doi: 10.1186/s40880-016-0096-0.
5
Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma.比较 NK/T 细胞淋巴瘤的上呼吸道和非上呼吸道病变。
Clin Transl Oncol. 2024 Jan;26(1):214-224. doi: 10.1007/s12094-023-03238-x. Epub 2023 Jun 23.
6
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).异环磷酰胺、甲氨蝶呤、依托泊苷和泼尼松龙(IMEP)联合L-天冬酰胺酶作为一线治疗方案可改善Ⅲ/Ⅳ期鼻型自然杀伤/T细胞淋巴瘤(NTCL)的预后。
Ann Hematol. 2015 Mar;94(3):437-44. doi: 10.1007/s00277-014-2228-4. Epub 2014 Oct 11.
7
Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type.基于治疗前βLRI和LLRI的鼻腔型IE/IIE期上消化道鼻型结外NK/T细胞淋巴瘤新预后模型的开发
Oncotarget. 2017 May 23;8(21):34787-34795. doi: 10.18632/oncotarget.16720.
8
When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?对于结外 NK/T 细胞淋巴瘤,鼻型患者,我们何时需要进行中枢神经系统预防?
Ann Oncol. 2010 May;21(5):1058-63. doi: 10.1093/annonc/mdp412. Epub 2009 Oct 22.
9
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type.在Ⅰ(E)/Ⅱ(E)期结外NK/T细胞淋巴瘤鼻型中,局部肿瘤侵袭性比国际预后指数更能预测生存率。
Blood. 2005 Dec 1;106(12):3785-90. doi: 10.1182/blood-2005-05-2056. Epub 2005 Aug 18.
10
[Misdiagnosis analysis: 120 patients with nasal extranodal NK/T cell lymphoma in head and neck].误诊分析:120例头颈部鼻型结外NK/T细胞淋巴瘤患者
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Jan;34(1):73-78. doi: 10.13201/j.issn.1001-1781.2020.01.018.

引用本文的文献

1
Prognostic value of interim [F]FDG PET/CT after immunotherapy-based combinations in extranodal NK/T-cell lymphoma, nasal type.基于免疫疗法的联合治疗后,[F]FDG PET/CT中期检查对鼻型结外NK/T细胞淋巴瘤的预后价值
Eur Radiol. 2025 Jan 21. doi: 10.1007/s00330-024-11276-4.
2
A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter study.晚期结外自然杀伤/T细胞淋巴瘤的预后指数:一项多中心研究。
Ann Hematol. 2025 Jan;104(1):445-455. doi: 10.1007/s00277-024-06160-6. Epub 2025 Jan 8.
3
Minimal residual disease detection in lymphoma: methods, procedures and clinical significance.
淋巴瘤微小残留病灶检测:方法、程序及临床意义。
Front Immunol. 2024 Aug 12;15:1430070. doi: 10.3389/fimmu.2024.1430070. eCollection 2024.
4
Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma.PD-L1 和 IDO1 的共表达增加与 NK/T 细胞淋巴瘤患者的总体生存不良相关。
Leukemia. 2024 Jul;38(7):1553-1563. doi: 10.1038/s41375-024-02266-y. Epub 2024 May 23.
5
Artificial intelligence for diagnosis and prognosis prediction of natural killer/T cell lymphoma using magnetic resonance imaging.基于磁共振成像的自然杀伤/T 细胞淋巴瘤诊断和预后预测的人工智能。
Cell Rep Med. 2024 May 21;5(5):101551. doi: 10.1016/j.xcrm.2024.101551. Epub 2024 May 1.
6
Extranodal NK/T-Cell Lymphoma, Nasal Type, Extranasal and Ulcerative Blister Variant, Case Report.鼻型结外NK/T细胞淋巴瘤,鼻外型及溃疡性水疱变体,病例报告
Ann Dermatol. 2023 Nov;35(Suppl 2):S304-S309. doi: 10.5021/ad.21.317.
7
Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma.比较 NK/T 细胞淋巴瘤的上呼吸道和非上呼吸道病变。
Clin Transl Oncol. 2024 Jan;26(1):214-224. doi: 10.1007/s12094-023-03238-x. Epub 2023 Jun 23.
8
Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.两种基于 L-天冬酰胺酶的化疗方案治疗初诊鼻腔型结外 NK/T 细胞淋巴瘤的临床疗效比较。
Cancer Med. 2023 Apr;12(8):9458-9470. doi: 10.1002/cam4.5708. Epub 2023 Mar 31.
9
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database.目前治疗结外鼻型自然杀伤/T 细胞淋巴瘤的治愈证据:CLC 数据库分析。
Haematologica. 2023 Sep 1;108(9):2467-2475. doi: 10.3324/haematol.2022.281847.
10
Treatment of extranodal NK/T-cell lymphoma: From past to future.结外 NK/T 细胞淋巴瘤的治疗:从过去到未来。
Front Immunol. 2023 Feb 7;14:1088685. doi: 10.3389/fimmu.2023.1088685. eCollection 2023.